Protea Sectoral Healthcare Opps PF $
Rating and Score (On 30/06/2026)
Rating
FIDA
Rating
ESG
FIDA Category
***Some functions are not available in this version.***
Register for free to unlock functions
Static data
Name | Protea Sectoral Healthcare Opps PF $ |
Typology | Funds and Sicav |
ISIN Code | LU2034586904 |
Sicav | Protea Fund |
Registration country | - |
Country authorised for sale | |
Asset manager | |
Address | 15, avenue J.F. Kennedy L-1855 Luxembourg |
Phone | |
Web site | |
FIDA Category | |
Assogestioni category | |
EFAMA Category | Equity Health Care |
Priips | Yes |
Official benchmark | - |
Start Date placement | 22/11/2019 |
Search by currency | Usd - us dollar |
Quotation currency | Usd - us dollar |
Status | Active |
Distribution policy | No |
Total asset value at - | - |
Documentation |
Quotation evolution (From 31/07/2023 On 31/07/2026)
35.48
12.07
%
31/07/2026
Loading data
Quote
Quotation currency | Usd - us dollar |
Quotation frequency | Daily |
Last quotation | $35.48 (31/07/2026) |
% change | |
Last Price in Euro | €30.89 |
Investment Objective
Objectives and investment policy The Sub-Fund is suitable for long term investment and constitutes an equity investment to add diversification to balanced portfolios. Investors should be aware of the risks linked to a higher profit potential of equity investments. The Sub-Fund invests primarily in innovative healthcare companies developing differentiated drugs, services, life science tools and devices in therapeutic areas with large unmet medical needs. Investments are made across all market caps and geographies, including the emerging markets, with significant exposure to mid- and small-cap companies, due to their high degree of innovation. Novel and differentiated treatments, devices, and services benefit from a favorable regulatory and commercial environment, with the potential for shortened development timelines, rapid market adoption as well as strong pricing and operating margins. Innovation in healthcare delivery and novel therapeutic modalities has created new business models and markets with tremendous commercial potential. In order to achieve this objective, the Sub-Fund invests, while respecting the principle of risk diversification, primarily in equities (including, but not limited to, common stocks, preferred stocks, or other securities convertible into common stock) and equity related securities (such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs), European Depositary Receipts (EDRs)) issued by mid and large cap issuers which are located worldwide (with a maximum exposure of 33% to emerging markets) and which are active in the following healthcare sectors: healthcare equipment and services, pharmaceuticals, biotechnology and life sciences. The Sub-Fund may, invest in transferable securities and money market instruments from new issues to benefit from particularly innovative projects in the healthcare sector. The Sub-Fund may invest up to 33% of its net assets via Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock C |
Tax system
PIR compliant | No |
PEA compliant | No |
PEA-PME compliant | No |
Company registry
Asset manager | |
Phone | |
Web site | |
Address | 15, avenue J.F. Kennedy L-1855 Luxembourg |
The data and information covered by the Service are for the exclusive internal use of the User and may neither be transferred to third parties, nor circulated, disclosed or allowed to be disclosed, nor used on external information systems, without the written consent of FIDA and, when necessary, of the information sources.
